SGEN Seagen
WatchlistSeagen News
FDA to Decide on Approving Keytruda/Padcev Combo Therapy by May 9
Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment
Merck (MRK) said late Thursday that the US Food and Drug Administration accepted for priority review a new supplemental biologics license application seeking approval for a combination of Keytruda and
Express News | Seagen Says FDA Grants Priority Review For Supplemental Biologics License Application (SBLA) Of PADCEV (Enfortumab Vedotin-ejfv) With KEYTRUDA (Pembrolizumab) For First-Line Treatment Of Advanced Bladder Cancer
AbbVie to Acquire Cancer Drugmaker ImmunoGen for $10B Cash
Pfizer CFO Reiterates Seagen Closing Expected Later This Year, Early Next Year
Unusual Options Activity: LEGN, SGEN and Others Attract Market Bets, LEGN V/OI Ratio Reaches 1000.0
EST Nov 27th Closing Delivery - In the last 3 hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Daiichi Sankyo Wins Favorable Final Arbitration Ruling in Dispute With Seagen
Daiichi Sankyo (TYO:4568) received a favorable final arbitration ruling in an intellectual property dispute with Seagen, according to a Monday bourse filing. Seagen was ordered to pay about $45.5 mill
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 17.92% on an annualized basis producing an average annual return of 29.45%. Currently, Seagen has a market capitalization of $
Tudor Investment Opens New Seagen, AbbVie Bets; Exits Immersion, Lennox
Unusual Options Activity: AZN, ROST and Others Attract Market Bets, AZN V/OI Ratio Reaches 3500.0
EST Nov 15th Morning Delivery - In the last 2 hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Seagen Inc CEO David Epstein Sells Over 10,000 Shares: An Insider Sell Analysis
Seagen(SGEN.US) Officer Sells US$2.26 Million in Common Stocks
$Seagen(SGEN.US)$ Officer Epstein David R sold 10,620 shares of Common Stocks on Nov 10, 2023 at an average price of $213.01 for a total value of $2.26 million.Source: Announcement What is statement o
Seagen(SGEN.US) Officer Sells US$1.87 Million in Common Stocks
$Seagen(SGEN.US)$ Officer HIMES VAUGHN B sold 8,785 shares of Common Stocks on Nov 9, 2023 at an average price of $213.32 for a total value of $1.87 million.Source: Announcement What is statement of c
Pfizer May File Substantial Compliance With FTC on Seagen in 3-4 Weeks - CNBC
Sen. Elizabeth Warren Tells FTC She Remains Concern About Amgen's Horizon Deal
Unusual Options Activity: SGEN, XPO and Others Attract Market Bets, SGEN V/OI Ratio Reaches 114.3
EST Nov 9th Afternoon Delivery - In the last 2 hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
Seagen (SGEN) Receives a Buy From Oppenheimer
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
On CNBC's "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc. (NASDAQ:DOCU) is "going to have to come up with something new and different and special, because right now, what they're doing
Analysts Have Conflicting Sentiments on These Healthcare Companies: Seagen (SGEN), IQVIA Holdings (IQV) and C4 Therapeutics (CCCC)
Cramer's Lightning Round: Sell Seagen
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.